Ord Minnett leads deal with Recce Pharmaceuticals

Ord Minnett has announced it has acted as Sole Lead Manager to Recce Pharmaceuticals Ltd (ASX:RCE) $10.0 million institutional placement and SPP.

‍

Proceeds from the equity raising will be used to advance clinical trials in intravenous and topical applications of Recce’s anti-infectives including Phase III registrational topical clinical trial in Indonesia, presenting an opportunity for an accelerated path to market and the catalyst for revenues in FY26.

‍

The placement was well bid for by new and existing institutional investors resulting in an upsizing of the deal and several new institutional investors introduced to the register including leading Australian impact fund NorthStar Impact, a European Sovereign Wealth Fund and follow-on support from Fidelity International.

‍

Damien Menzies, Managing Director said: “Ord Minnett is pleased to support Recce in its equity raising, which will enable the company to progress clinical trials and embark on an accelerated path to market. We congratulate James Graham, John Prendergast and the entire Recce team on a successful transaction and look forward to continuing our support.”